However, emerging studies aim to HCC or ICC molecular subclassification associated with subtype-related target therapy.15, 25, 26, 27, 28, 29 Studies such as whole-genome sequencing (WGS) of HCC reveal frequent mutations in various tumor suppressor genes and oncogenes, including telomerase reverse transcriptase promoter mutations (54–60%), catenin beta 1 (CTNNB1) mutations (11–37%), tumor protein P53 (TP53) mutations (12–48%) and AT-rich interactive domain-containing protein 1A (ARID1A) mutations (4–17%).30, 31, 32, 33 However, mutation-specific subtypes are not evident. The gene discussed is ARID1A; the disease is hepatocellular carcinoma.